It's been a tumultous two months for the health care industry in China. Big pharma's fortunes have turned sour in a heartbeat after Beijing's investigations into GlaxoSmithKline (NYSE: GSK) -- which resulted in a number of arrests -- have morphed into probes of numerous countries in the world's hottest emerging markets. With many health care companies looking toward China and other developing economies for the future, the escalating situation has turned into a giant headache.
China's reportedly expanding its probes far beyond pharmaceutical companies -- and even the health care sector at large. However, for medical device makers, it's time to start paying attention to China's investigations if you haven't been so far.
According to Reuters, an industry body in China has begun investigating device makers in the country for any signs of price-fixing behavior. Nothing has turned up so far, but just how could this situation play out for the industry's top companies in the nation -- and in your portfolio? Fool contributor Dan Carroll explains the latest in the video below and tells you which companies have the most to lose in this fast-growing market.
Investing in China's a tricky business, between the price-fixing investigation to the country's recent slowdown that has Wall Street worried. Fortunately, you don't have to know China backwards and forwards to make money off of the world's hottest emerging markets. Profiting from our increasingly global economy can be as easy as investing in your own backyard. The Motley Fool's free report "3 American Companies Set to Dominate the World" shows you how. Click here to get your free copy before it's gone.